Who
Lisa Rojkjaer
EVP, Chief Medical Officer
Company insider
Files Form 4 as: EVP, Chief Medical Officer, Rigel Pharmaceuticals; Chief Medical Officer, Viracta Therapeutics.
In numbers
- Trades disclosed
- 41
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $51K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 26 Mar 2021
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,375 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,375 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $25K850 at $29.86 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $25K850 at $29.86 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —18,894 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —18,894 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $130K3,758 at $34.62 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $130K3,758 at $34.62 | filing |
| 15 Sep 2025filed 17 Sep 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,375 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,788 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —19,717 at $0.00 | filing |
| 27 Mar 2024filed 29 Mar 2024 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —187,500 at $0.00 | filing |
| 16 Mar 2023filed 17 Mar 2023 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 27 Feb 2023filed 28 Feb 2023 | Viracta Therapeutics | SEC FORM 4 Sold | $3,6222,156 at $1.68 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code M | —4,127 at $0.00 | filing |
| 25 Feb 2023filed 28 Feb 2023 | Viracta Therapeutics | SEC FORM 4 Code M | —4,127 at $0.00 | filing |
| 28 Nov 2022filed 29 Nov 2022 | Viracta Therapeutics | SEC FORM 4 Sold | $5,7562,116 at $2.72 | filing |
News
No headline names them, or the companies they trade most, lately.